Table 2.
Factors associated with 6-week mortality in cirrhotic patients with acute variceal bleeding
| Risk factors | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Age | 1.086 (1.026–1.150) | 0.005 | 1.071 (1.005–1.141) | 0.035 |
| Female | 0.466 (0.125–1.739) | 0.256 | ||
| Etiology of cirrhosis (virus) | 1.063 (0.681–1.660) | 0.787 | ||
| HCC within Milan criterion | 8.625 (2.511–29.631) | 0.001 | 3.105 (1.005–1.141) | 0.244 |
| Decompensation at admission | ||||
| Ascites | 6.761 (0.863–52.954) | 0.069 | ||
| Hepatic encephalopathy | 2.701 (0.545–13.391) | 0.224 | ||
| Bacterial infection | 5.102 (1.601–16.261) | 0.006 | 2.360 (1.048–5.315) | 0.038 |
| Rebleeding | 3.659 (0.098–17.915) | 0.006 | 3.659 (0.098–17.915) | 0.098 |
| Laboratory tests | ||||
| White blood cell | 1.150 (1.111–1.280) | 0.032 | 1.009 (0.803–1.269) | 0.937 |
| Hemoglobin | 0.984 (0.954–1.016) | 0.323 | ||
| Platelet | 1.000 (0.991–1.010) | 0.919 | ||
| Albumin | 0.926 (0.825–1.038) | 0.185 | ||
| Total bilirubin | 1.016 (1.000–1.031) | 0.044 | 1.003 (0.979–1.028) | 0.810 |
| Alanine aminotransferase | 1.006 (0.998–1.016) | 0.156 | ||
| Aspartate aminotransferase | 1.015 (1.002–1.028) | 0.024 | 1.013 (0.995–1.031) | 0.148 |
| International normalized ratio | 4.542 (0.697–29.612) | 0.114 | ||
| Prothrombin time | 1.143 (0.975–1.341) | 0.099 | ||
| Serum creatinine | 1.031 (1.010–1.053) | 0.004 | 1.021 (0.998–1.046) | 0.079 |
| Serum sodium | 0.773 (0.669–0.892) | <0.001 | 0.817 (0.684–0.976) | 0.026 |
| Serum potassium | 4.906 (1.618–14.879) | 0.005 | 0.763 (0.140–4.160) | 0.754 |
| Prognosis scores | ||||
| CLIF-C AD | 1.192 (1.100–1.290) | <0.001 | ||
| CTP | 1.426 (1.113–1.827) | 0.005 | ||
| MELD | 1.298 (1.111–1.517) | 0.001 | ||
| MELD-Na | 1.246 (1.122–1.384) | <0.001 | ||
Bold values indicate statistical significance.
CI, confidence interval; CLIF-C AD, Chronic Liver Failure-Consortium Acute Decompensation; CTP, Child-Turcotte-Pugh; HCC, hepatocellular carcinoma; MELD, Model for End-stage Liver Disease; MELD-Na, MELD-Sodium; OR, odds ratio.